ATE219522T1 - Hepatistherapeutikum - Google Patents

Hepatistherapeutikum

Info

Publication number
ATE219522T1
ATE219522T1 AT93904901T AT93904901T ATE219522T1 AT E219522 T1 ATE219522 T1 AT E219522T1 AT 93904901 T AT93904901 T AT 93904901T AT 93904901 T AT93904901 T AT 93904901T AT E219522 T1 ATE219522 T1 AT E219522T1
Authority
AT
Austria
Prior art keywords
hepatist
therapeutic
infections
hepatitis
treating hepatitis
Prior art date
Application number
AT93904901T
Other languages
English (en)
Inventor
Douglas J Jolly
Stephen M W Chang
William Tsung-Liang Lee
Kay Townsend
Joann O'dea
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25256972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE219522(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE219522T1 publication Critical patent/ATE219522T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Catching Or Destruction (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT93904901T 1992-02-04 1993-02-04 Hepatistherapeutikum ATE219522T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83041792A 1992-02-04 1992-02-04
PCT/US1993/001009 WO1993015207A2 (en) 1992-02-04 1993-02-04 Hepatitis therapeutics

Publications (1)

Publication Number Publication Date
ATE219522T1 true ATE219522T1 (de) 2002-07-15

Family

ID=25256972

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93904901T ATE219522T1 (de) 1992-02-04 1993-02-04 Hepatistherapeutikum

Country Status (10)

Country Link
EP (1) EP0625204B1 (de)
JP (3) JPH07503615A (de)
AT (1) ATE219522T1 (de)
AU (2) AU3610293A (de)
CA (1) CA2128896A1 (de)
DE (1) DE69332045T2 (de)
DK (1) DK0625204T3 (de)
ES (1) ES2174845T3 (de)
PT (1) PT625204E (de)
WO (1) WO1993015207A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297048B1 (en) 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
ES2197170T3 (es) 1993-11-04 2004-01-01 Innogenetics N.V. Epitopos de celulas t humanas inmunologicamente dominantes del virus de la hepatitis c.
DE69535669T2 (de) 1994-05-09 2008-12-04 Oxford Biomedica (Uk) Ltd. Retrovirale vektoren mit verminderter rekombinationsrate
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
NZ296304A (en) * 1994-10-05 1999-06-29 Apollon Hepatitis c vaccine components
US6235888B1 (en) 1994-10-05 2001-05-22 The General Hospital Corporation Hepatitis C virus vaccine
US5856169A (en) * 1995-02-21 1999-01-05 Thomas Jefferson University Isoforms of human interleukin-1β converting enzyme and methods of using the same
RU2189254C2 (ru) * 1995-06-06 2002-09-20 Америкэн Хоум Продактс Корпорэйшн Вакцины против вирусов гепатита
ES2301178T3 (es) 1996-04-05 2008-06-16 Novartis Vaccines & Diagnostic Vectores basados en alfavirus recombinantes con inhibicion reducida de la sintesis macromolecular celular.
DK1077722T3 (da) 1998-05-22 2006-11-27 Ottawa Health Research Inst Fremgangsmåder og produkter til induktion af mukosaimmunitet
NZ540098A (en) 2002-10-29 2008-09-26 Coley Pharmaceutical Group Ltd Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
JP4474198B2 (ja) * 2004-05-19 2010-06-02 株式会社日立ハイテクノロジーズ Ｃ型肝炎ウイルス恒温増幅用プライマー
WO2009022236A2 (en) * 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
KR102198749B1 (ko) * 2011-03-02 2021-01-06 제롬 쉔타그 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU612983B2 (en) * 1986-08-01 1991-07-25 Australian National University, The Recombinant vaccine
WO1988006185A1 (en) * 1987-02-11 1988-08-25 Scripps Clinic And Research Foundation Retroviral expression vectors and methods for producing hbv antigens
WO1991015596A1 (en) * 1990-04-04 1991-10-17 Protos, Inc. Hepatitis c virus protease inhibitors
KR100206150B1 (ko) * 1990-04-04 1999-07-01 로버트 피. 블랙버언 항-에이치씨브이 항체에 대한 면역분석용 씨형 간염 바이러스(에이치디브이)항원의 조합체
FI913068A7 (fi) * 1990-06-25 1991-12-26 The Res Foundation For Microbial Ei-A-, ei-B-hepatiittiviruspartikkelit
CA2049679C (en) * 1990-08-24 2005-06-21 Sushil G. Devare Hepatitis c assay utilizing recombinant antigens

Also Published As

Publication number Publication date
WO1993015207A2 (en) 1993-08-05
PT625204E (pt) 2002-10-31
JP2000154152A (ja) 2000-06-06
CA2128896A1 (en) 1993-08-05
ES2174845T3 (es) 2002-11-16
EP0625204A1 (de) 1994-11-23
DE69332045T2 (de) 2002-10-17
DK0625204T3 (da) 2002-07-15
DE69332045D1 (de) 2002-07-25
JPH07503615A (ja) 1995-04-20
JP2003055265A (ja) 2003-02-26
AU7530996A (en) 1997-02-20
AU3610293A (en) 1993-09-01
WO1993015207A3 (en) 1994-01-06
EP0625204B1 (de) 2002-06-19

Similar Documents

Publication Publication Date Title
DE69332045D1 (de) Hepatistherapeutikum
RU93058676A (ru) Оральное лечение геликобактерной инфекции
ATE512224T1 (de) Rekonstituierter menschlicher anti-hm.1 antikörper
ATE177755T1 (de) Hybrides protein zwischen cs aus plasmodium und hbsag
GB2272443A (en) Hepatitis C diagnostics and vaccines
DK0992580T3 (da) Epitoper på human T-celler, som er immundominante for hepatitis C-virus
LU88365I2 (fr) Hbvax vaccin recombinant contenant une protéine HBsAG pour une immunisation active contre des infections dues à l'hépatite B.
DE60039715D1 (de) Hcv-impfstoff zusammensetzungen
ATE233814T1 (de) Humaner neutralisierender monoklonaler antikörper gegen den die immunschwäche beim menschen hervorringenden virus
HU9301794D0 (en) Medical preparative for treating chronical viral diseases of liver as well qs method for preparing said medicament
IL96893A0 (en) Vaccines against cancer and infectious diseases
NO941310L (no) Sammensetning og fremgangsmåte for behandling av hepatitt C
DE3479583D1 (en) High titer cytomegalovirus human immune serum globulin and method of making same
NO912825D0 (no) Fremgangsmaate for fremstilling av cokonjugate vaksiner omfattende immunogenisk protein, hiv-beslektede peptider og anioniske grupper.
DK0552240T3 (da) Ny metode til behandling af depression
DK0546076T3 (da) Anvendelse af anti-ICAM antistoffer til fremstilling af et lægemiddel til behandling af endotoksiskshock
NO951747D0 (no) Fremgangsmåte ved fremstilling av xylitol
ATE359089T1 (de) Peptide zum induzieren einer antwort der zytotoxischen t-lymphozyten gerichtet gegen das hepatitis-b-virus
ATE157259T1 (de) Verbesserte adjuvantien und impfstoffe
EP0881910A4 (de) Verwendung von immunokonjugaten zur erhöhung der effektivität von mehrstufigen kaskaden-impfstoffen
NL300336I2 (nl) Vaccin tegen de bof dat een jeryl-lynn virusstam bevat
EP0600396A3 (de) Darmprotozoe Impfstoffe.
PH31116A (en) Methods for the treatment of infection caused by hepatitis B virus (hbv).
ATE285791T1 (de) Impfstoff, der acemannan als adjuvans enthält
MX9203348A (es) Nuevo metodo de induccion de ovulacion en humanos.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee